Market Access Impact: Asthma/COPD (US)
Three brands top the list in the US as the most prescribed treatments for asthma and COPD, but are these the preferred options or are market barriers pushing physicians toward them? Delve behind the headline numbers and find out the constraints impacting decision-making - to the benefit of some brands and the detriment of others.
This new report from FirstView, Market Access Impact: Asthma/COPD, assesses current barriers and their effects for 12 leading asthma/COPD drugs from GSK, Novartis, AstraZeneca, Boehringer Ingelheim and Roche.
Use this powerful insight into physician thinking to optimise your market access strategy and increase market penetration.
We surveyed 100 pulmonologists in the US, chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between the 8th and 13th June 2016.